Evaxion A-S

Evaxion A‑S insiders hold 36,765 shares and long‑term warrants, signalling confidence in its AI‑driven vaccine pipeline and potential price rally after key clinical milestones.

CEO‑held shares, warrant vesting, and insider momentum signal strong confidence in Evaxion A‑S’s oncology pipeline and upcoming partnership prospects.